Editas Medicine Management

Management Kriterienprüfungen 2/4

Editas Medicine CEO ist Gilmore O’Neill , ernannt in Jun 2022, hat eine Amtszeit von 2.42 Jahren. Die jährliche Gesamtvergütung beträgt $2.39M , bestehend aus 26.8% Gehalt und 73.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.13% der Aktien des Unternehmens, im Wert von $239.66K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.7 Jahre bzw. 3.9 Jahre.

Wichtige Informationen

Gilmore O’Neill

Geschäftsführender

US$2.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	26.8%
Amtszeit als Geschäftsführer	2.4yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	1.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Gilmore O’Neill im Vergleich zu den Einnahmen von Editas Medicine verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$211m
Jun 30 2024	n/a	n/a	-US$193m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

Vergütung im Vergleich zum Markt: GilmoreDie Gesamtvergütung ($USD2.39M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD743.85K).

Entschädigung vs. Einkommen: GilmoreDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Gilmore O’Neill (60 yo)

2.4yrs

Amtszeit

US$2,392,309

Vergütung

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gilmore O’Neill	President	2.4yrs	US$2.39m	0.13% $ 239.7k
Erick Lucera	CFO & Executive VP	1.5yrs	US$2.69m	0.028% $ 51.1k
Linda Burkly	Executive VP & Chief Scientific Officer	1.3yrs	US$1.73m	0.018% $ 32.0k
Baisong Mei	Executive VP & Chief Medical Officer	2.3yrs	US$1.14m	0.052% $ 94.1k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.8yrs	keine Daten	keine Daten
George Church	Co-Founder & Scientific Advisory Board Member	11.8yrs	keine Daten	keine Daten
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	keine Daten	keine Daten
Cristi Barnett	Corporate Communications & Investor Relations	no data	keine Daten	keine Daten
Charlene Stern	Executive VP & General Counsel	no data	keine Daten	keine Daten
Linea Aspesi	Executive VP & Chief People Officer	1.7yrs	keine Daten	keine Daten
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	1.2yrs	keine Daten	keine Daten

1.7yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: 0IFKDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.7 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gilmore O’Neill	President	no data	US$2.39m	0.13% $ 239.7k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	keine Daten	keine Daten
George Church	Co-Founder & Scientific Advisory Board Member	no data	keine Daten	keine Daten
Emma Reeve	Independent Chairman of the Board	3.2yrs	US$238.24k	0% $ 0
Andrew Hirsch	Independent Director	7.5yrs	US$210.56k	0.0024% $ 4.4k
Jessica Hopfield	Independent Director	6.8yrs	US$231.07k	0.082% $ 149.6k
Elliott Levy	Independent Director	1.6yrs	US$264.88k	0% $ 0
David Scadden	Independent Director	5.8yrs	US$213.06k	0% $ 0
Bernadette Connaughton	Independent Director	3.1yrs	US$215.06k	0% $ 0
Meeta Chatterjee	Independent Director	3.9yrs	US$205.56k	0% $ 0

3.9yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: 0IFKDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

Editas Medicine Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

President recently sold US$67k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

New major risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

Independent Lead Director recently bought US$254k worth of stock

First quarter 2024 earnings released: US$0.76 loss per share (vs US$0.71 loss in 1Q 2023)

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Full year 2023 earnings released: US$2.02 loss per share (vs US$3.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.81 loss in 3Q 2022)

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.78 loss in 2Q 2022)

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Insider recently sold US$62k worth of stock

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.21 loss per share (vs US$2.85 loss in FY 2021)

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2021)

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.81 loss in 2Q 2021)

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.86 loss in 1Q 2021)

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold US$492k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Executive VP & Chief Medical Officer recently sold US$60k worth of stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)

Chairman recently bought US$1.2m worth of stock

Full year 2020 earnings released: US$1.98 loss per share (vs US$2.68 loss in FY 2019)

Revenue beats expectations

Editas Medicine Announces Update on Clinical Updates

Editas Medicine, Inc. Appoints James C. Mullen as President

President recently sold US$84k worth of stock

Editas Medicine, Inc. Announces Management Changes, Effective February 15, 2021

CFO, Principal Accounting Officer recently sold US$123k worth of stock

Editas Medicine, Inc. Announces Steps Down of Charles Albright as Chief Scientific Officer, Effective January 15

Editas Medicine, Inc. Names Meeta Chatterjee, Ph.D., to Board of Directors